Výsledky vyhledávání - Mahtab Marker

  • Zobrazuji výsledky 1 - 9 z 9
Upřesnit hledání
  1. 1
    Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

    Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study Autor Alessandro M. Vannucchi, Srđan Verstovšek, Paola Guglielmelli, Martin Grießhammer, Timothy C. Burn, Ahmad Naim, Dilan Paranagama, Mahtab Marker, Brian Gadbaw, Jean‐Jacques Kiladjian

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

    Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma Autor Martin H. Voss, David Chen, Mahtab Marker, A. Ari Hakimi, Chung‐Han Lee, James J. Hsieh, Jennifer J. Knox, Maurizio Voi, Robert J. Motzer

    Vydáno 2016
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study

    Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study Autor Martin H. Voss, Albert Reising, Yuan Cheng, Parul Patel, Mahtab Marker, Fengshen Kuo, Timothy A. Chan, Toni K. Choueiri, James J. Hsieh, A. Ari Hakimi, Robert J. Motzer

    Vydáno 2018
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

    Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study Autor Mahrukh M. Syeda, Jennifer Wiggins, Broderick C. Corless, Georgina V. Long, Keith T. Flaherty, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Michael A. Davies, Jean‐Jacques Grob, Eduard Gasal, Matthew Squires, Mahtab Marker, James E. Garrett, Jan C. Brase, David Polsky

    Vydáno 2021
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial

    Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial Autor A. Ari Hakimi, Martin H. Voss, Fengshen Kuo, Alejandro Sánchez, Ming Liu, Briana G. Nixon, Lynda Vuong, Irina Ostrovnaya, Ying‐Bei Chen, Victor E. Reuter, Nadeem Riaz, Yuan Cheng, Parul Patel, Mahtab Marker, Albert Reising, Ming O. Li, Timothy A. Chan, Robert J. Motzer

    Vydáno 2019
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

    Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC Autor Jennifer J. Knox, Carlos H. Barrios, T.M. Kim, Thomas M. Cosgriff, Vichien Srimuninnimit, K. Pittman, Roberto Sabbatini, Sun Young Rha, Thomas W. Flaig, Ray D. Page, J. Thaddeus Beck, Florence Cheung, S. Yadav, Poulam M. Patel, Lionnel Geoffrois, Julie Niolat, Noah Berkowitz, Mahtab Marker, Dehui Chen, Robert J. Motzer

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial Autor Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang, Cora N. Sternberg, Cezary Szczylik, Jakub Żołnierek, Christian Kollmannsberger, Sun Young Rha, Georg A. Bjarnason, Bohuslav Melichar, Ugo De Giorgi, Viktor Grünwald, Ian D. Davis, Jae‐Lyun Lee, Emilio Esteban, Gladys Urbanowitz, Can Cai, Matthew Squires, Mahtab Marker, Michael Shi, Bernard Escudier

    Vydáno 2014
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

    A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts Autor Guillermo Garcia‐Manero, Mikkael A. Sekeres, Miklós Egyed, Massimo Breccia, Carlos Graux, Jamie Cavenagh, H Salman, Árpád Illés, Pierre Fenaux, Daniel J. DeAngelo, Reinhard Stauder, Karen Yee, Nancy Zhu, Je‐Hwan Lee, David Valcárcel, Alan Macwhannell, Z Borbényi, Lucien Gazi, Suddhasatta Acharyya, Susan Ide, Mahtab Marker, Oliver G. Ottmann

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma

    Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma Autor James J. Hsieh, David Chen, Patricia I. Wang, Mahtab Marker, Almedina Redzematovic, Ying‐Bei Chen, S. Duygu Selçuklu, Nils Weinhold, Nancy Bouvier, Kety Huberman, Umesh Bhanot, Michael Chevinsky, Parul Patel, Patrizia Pinciroli, Helen Won, Daoqi You, Agnès Viale, William Lee, A. Ari Hakimi, Michael F. Berger, Nicholas D. Socci, Emily H. Cheng, Jennifer J. Knox, Martin H. Voss, Maurizio Voi, Robert J. Motzer

    Vydáno 2016
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: